John P. Schmid
CIK 1478916 · Chief Financial Officer · last filed 2026-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.37M
Companies
9
Total Filings
79
Lifetime Open-Market Net
-$1.09M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DSGN | Director | 57,639 | $10.97 | $632.3K | $99.7K | 7 | 2026-06-11 |
| TRAX | Director | 31,622 | — | — | $0 | 2 | 2026-05-14 |
| ANAB | Director | 32,144 | $56.07 | $1.80M | -$1.16M | 17 | 2026-04-22 |
| BridgeBio Oncology Therapeutics, Inc. (HLXB) Delisted | 30,000 | $9.90 | $297.0K | $0 | 1 | 2025-08-11 | |
| Poseida Therapeutics, Inc. (PSTX) Delisted | Director | 0 | $9.50 | $0 | $0 | 7 | 2025-01-08 |
| XERS | Director | 138,359 | $6.79 | $939.5K | $50.1K | 12 | 2024-08-13 |
| Neos Therapeutics, Inc. (NEOS) Delisted | Director | 0 | $1.15 | $0 | $0 | 6 | 2021-03-19 |
| Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Chief Financial Officer | 0 | — | — | $0 | 2 | 2015-05-06 |
| Trius Therapeutics Inc (TSRX) Delisted | Chief Financial Officer | 107,639 | — | — | -$85.0K | 23 | 2013-03-11 |
Recent Filings · Page 2 of 8
79 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-03-27 | ANAB | Other (J) | +11,068 | $201.2K | EDGAR |
| 2025-01-15 | ANAB | Exer (M) | +42,337 | $275.0K | EDGAR |
| 2025-01-08 | Poseida Therapeutics, Inc. (PSTX) Delisted | Mixed | −58,950 | $0 | EDGAR |
| 2025-01-07 | ANAB | Grant (A) | — | $0 | EDGAR |
| 2024-08-13 | XERS | Buy (P) | +4,515 | $10.1K | EDGAR |
| 2024-08-12 | XERS | Buy (P) | +4,285 | $10.1K | EDGAR |
| 2024-06-18 | ANAB | Exer (M) | +3,900 | $0 | EDGAR |
| 2024-06-18 | Poseida Therapeutics, Inc. (PSTX) Delisted | Grant (A) | +19,650 | $0 | EDGAR |
| 2024-06-17 | DSGN | Grant (A) | — | $0 | EDGAR |
| 2024-06-05 | XERS | Grant (A) | +50,000 | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.